HSP27 expression regulates CCK-induced changes of the actin cytoskeleton in CHO-CCK-A cells.
We investigated how heat shock protein 27 (HSP27) and its phosphorylation are involved in the action of cholecystokinin (CCK) on the actin cytoskeleton by genetic manipulation of Chinese hamster ovary (CHO) cells stably transfected with the CCK-A receptor. In these cells, as in rat acini, CCK activated p38 mitogen-activated protein (MAP) kinase and increased the phosphorylation of HSP27. This effect could be blocked with the p38 MAP kinase inhibitor SB-203580. Examination by confocal microscopy of cells stained with rhodamine phalloidin showed that CCK dose-dependently induced changes of the actin cytoskeleton, including cell shape changes, which were coincident with actin cytoskeleton fragmentation and formation of actin filament patches in the cells. To further evaluate the role of HSP27, CHO-CCK-A cells were transfected with expression vectors for either wild-type (wt) or mutant (3A, 3G, and 3D) human HSP27. Overexpression of wt-HSP27 and 3D-HSP27 inhibited the effects on the actin cytoskeleton seen after high-dose CCK stimulation. In contrast, overexpression of nonphosphorylatable mutants, 3A- and 3G-HSP27, or inhibition of phosphorylation of HSP27 by preincubation of wt-HSP27 transfected cells with SB-203580 did not protect the actin cytoskeleton. These results suggest that phosphorylation of HSP27 is required to stabilize the actin cytoskeleton and to protect the cells from the effects of high concentrations of CCK.
Schäfer
C
C
Department of Physiology, University of Michigan, Ann Arbor, Michigan 48109-0622, USA.
Clapp
P
P
Welsh
M J
MJ
Benndorf
R
R
Williams
J A
JA
D008841:Actin Cytoskeleton / Q000378:metabolism*; D000199:Actins / Q000032:analysis / Q000378:metabolism*; D000208:Acute Disease; D000818:Animals; D016466:CHO Cells; D002458:Cell Fractionation; D002108:Ceruletide / Q000378:metabolism; D006224:Cricetinae; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D003902:Detergents; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D006360:Heat-Shock Proteins / Q000032:analysis / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000502:physiology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D016296:Mutagenesis / Q000502:physiology; D017830:Octoxynol; D010195:Pancreatitis / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000235:genetics*; D012844:Sincalide / Q000494:pharmacology*; D014162:Transfection; D048051:p38 Mitogen-Activated Protein Kinases
D000199:Actins; D016895:Culture Media, Serum-Free; D003902:Detergents; D004791:Enzyme Inhibitors; D006360:Heat-Shock Proteins; D007093:Imidazoles; D011725:Pyridines; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D002108:Ceruletide; D017830:Octoxynol; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D012844:Sincalide; C093642:SB 203580